Evotec Buys Cell-based Reagents Firm for up to $2.9M | GenomeWeb

NEW YORK (GenomeWeb News) – Evotec today announced it has acquired custom cell and cell-based reagents firm Cell Culture Service for up to €2.2 million ($2.9 million).

Evotec will pay €1.15 million in cash as part of the deal. CCS is also eligible for an earn-out payment of €1.05 million due one year after the acquisition and dependent on certain revenue targets being met.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.